Yang Q, Xu J, Gu J, Shi H, Zhang J, Zhang J, et al. Extracellular vesicles in Cancer Drug Resistance: roles, mechanisms, and implications. Adv Sci (Weinh). 2022;9:e2201609. https://doi.org/10.1002/advs.202201609.
Article CAS PubMed Google Scholar
De Las Rivas J, Brozovic A, Izraely S, Casas-Pais A, Witz IP, Figueroa A. Cancer drug resistance induced by EMT: novel therapeutic strategies. Arch Toxicol. 2021;95:2279–97. https://doi.org/10.1007/s00204-021-03063-7.
Article CAS PubMed Central Google Scholar
Ward RA, Fawell S, Floc’h N, Flemington V, McKerrecher D, Smith PD. Challenges and opportunities in Cancer Drug Resistance. Chem Rev. 2021;121:3297–351. https://doi.org/10.1021/acs.chemrev.0c00383.
Article CAS PubMed Google Scholar
Song H, Liu D, Dong S, Zeng L, Wu Z, Zhao P, et al. Epitranscriptomics and epiproteomics in cancer drug resistance: therapeutic implications. Signal Transduct Target Ther. 2020;5:193. https://doi.org/10.1038/s41392-020-00300-w.
Article PubMed PubMed Central Google Scholar
Di Donato M, Medici N, Migliaccio A, Castoria G, Giovannelli P. Exosomes: emerging modulators of pancreatic Cancer Drug Resistance. Cancers (Basel). 2023;15. https://doi.org/10.3390/cancers15194714.
Gonzalez-Fierro A, Dueñas-González A. Drug repurposing for cancer therapy, easier said than done. Semin Cancer Biol. 2021;68:123–31. https://doi.org/10.1016/j.semcancer.2019.12.012.
Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q, et al. Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther. 2023;8:204. https://doi.org/10.1038/s41392-023-01468-7.
Article PubMed PubMed Central Google Scholar
Chen S, Zhao Y, Liu S, Zhang J, Assaraf YG, Cui W, et al. Epigenetic enzyme mutations as mediators of anti-cancer drug resistance. Drug Resist Updat. 2022;61:100821. https://doi.org/10.1016/j.drup.2022.100821.
Article CAS PubMed Google Scholar
Jo H, Shim K, Jeoung D. Targeting HDAC6 to Overcome Autophagy-promoted Anti-cancer Drug Resistance. Int J Mol Sci. 2022;23. https://doi.org/10.3390/ijms23179592.
Chan YT, Lu Y, Wu J, Zhang C, Tan HY, Bian ZX, et al. CRISPR-Cas9 library screening approach for anti-cancer drug discovery: overview and perspectives. Theranostics. 2022;12:3329–44. https://doi.org/10.7150/thno.71144.
Article CAS PubMed PubMed Central Google Scholar
Gao L, Wu ZX, Assaraf YG, Chen ZS, Wang L. Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function. Drug Resist Updat. 2021;57:100770. https://doi.org/10.1016/j.drup.2021.100770.
Article CAS PubMed Google Scholar
Namee NM, O’Driscoll L. Extracellular vesicles and anti-cancer drug resistance. Biochim Biophys Acta Rev Cancer. 2018;1870:123–36. https://doi.org/10.1016/j.bbcan.2018.07.003.
Article CAS PubMed Google Scholar
Zhao Z, Mei Y, Wang Z, He W. The effect of oxidative phosphorylation on Cancer Drug Resistance. Cancers (Basel). 2022;15. https://doi.org/10.3390/cancers15010062.
Qin Y, Ashrafizadeh M, Mongiardini V, Grimaldi B, Crea F, Rietdorf K, et al. Autophagy and cancer drug resistance in dialogue: pre-clinical and clinical evidence. Cancer Lett. 2023;570:216307. https://doi.org/10.1016/j.canlet.2023.216307.
Article CAS PubMed Google Scholar
Pi M, Kuang H, Yue C, Yang Q, Wu A, Li Y, et al. Targeting metabolism to overcome cancer drug resistance: a promising therapeutic strategy for diffuse large B cell lymphoma. Drug Resist Updat. 2022;61:100822. https://doi.org/10.1016/j.drup.2022.100822.
Article CAS PubMed Google Scholar
Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006;5:219–34. https://doi.org/10.1038/nrd1984.
Article CAS PubMed Google Scholar
Gonçalves AC, Richiardone E, Jorge J, Polónia B, Xavier CPR, Salaroglio IC, et al. Impact of cancer metabolism on therapy resistance - clinical implications. Drug Resist Updat. 2021;59:100797. https://doi.org/10.1016/j.drup.2021.100797.
Article CAS PubMed Google Scholar
Wang J, Tian T, Li X, Zhang Y. Noncoding RNAs emerging as drugs or drug targets: their Chemical Modification, Bio-conjugation and Intracellular Regulation. Molecules. 2022;27. https://doi.org/10.3390/molecules27196717.
Zahedipour F, Jamialahmadi K, Karimi G. The role of noncoding RNAs and sirtuins in cancer drug resistance. Eur J Pharmacol. 2020;877:173094. https://doi.org/10.1016/j.ejphar.2020.173094.
Article CAS PubMed Google Scholar
Cui Q, Wang JQ, Assaraf YG, Ren L, Gupta P, Wei L, et al. Modulating ROS to overcome multidrug resistance in cancer. Drug Resist Updat. 2018;41:1–25. https://doi.org/10.1016/j.drup.2018.11.001.
Kong M, Yu X, Guo W, Guo R. The bidirectional interplay between ncRNAs and methylation modifications in gastrointestinal tumors. Int J Biol Sci. 2023;19:4834–48. https://doi.org/10.7150/ijbs.87028.
Article CAS PubMed PubMed Central Google Scholar
Zhang Z, Zhang C, Luo Y, Zhang G, Wu P, Sun N, et al. RNA N(6) -methyladenosine modification in the lethal teamwork of cancer stem cells and the tumor immune microenvironment: current landscape and therapeutic potential. Clin Transl Med. 2021;11:e525. https://doi.org/10.1002/ctm2.525.
Article CAS PubMed PubMed Central Google Scholar
Piperi C, Markouli M, Gargalionis AN, Papavassiliou KA, Papavassiliou AG. Deciphering glioma epitranscriptome: focus on RNA modifications. Oncogene. 2023;42:2197–206. https://doi.org/10.1038/s41388-023-02746-y.
Article CAS PubMed Google Scholar
Icard P, Shulman S, Farhat D, Steyaert JM, Alifano M, Lincet H. How the Warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1–11. https://doi.org/10.1016/j.drup.2018.03.001.
Wang N, Ma T, Yu B. Targeting epigenetic regulators to overcome drug resistance in cancers. Signal Transduct Target Ther. 2023;8:69. https://doi.org/10.1038/s41392-023-01341-7.
Article CAS PubMed PubMed Central Google Scholar
Li B, Jiang J, Assaraf YG, Xiao H, Chen ZS, Huang C. Surmounting cancer drug resistance: new insights from the perspective of N(6)-methyladenosine RNA modification. Drug Resist Updat. 2020;53:100720. https://doi.org/10.1016/j.drup.2020.100720.
Liu Z, Zou H, Dang Q, Xu H, Liu L, Zhang Y, et al. Biological and pharmacological roles of m(6)a modifications in cancer drug resistance. Mol Cancer. 2022;21:220. https://doi.org/10.1186/s12943-022-01680-z.
Article CAS PubMed PubMed Central Google Scholar
Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 2023;68:100938. https://doi.org/10.1016/j.drup.2023.100938.
Article CAS PubMed Google Scholar
Du B, Shim JS. Targeting epithelial-mesenchymal transition (EMT) to Overcome Drug Resistance in Cancer. Molecules. 2016;21. https://doi.org/10.3390/molecules21070965.
Xie W, Sun H, Li X, Lin F, Wang Z, Wang X. Ovarian cancer: epigenetics, drug resistance, and progression. Cancer Cell Int. 2021;21:434. https://doi.org/10.1186/s12935-021-02136-y.
Article CAS PubMed PubMed Central Google Scholar
Sun L, Zhang H, Gao P. Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2022;13:877–919. https://doi.org/10.1007/s13238-021-00846-7.
留言 (0)